Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine Deaminase
ACS Chemical Biology · 21.11.2025 · 20 (11) · 2593-2600
DOI: 10.1021/acschembio.5c00394 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 22.10.2025. Verfasst von Ramkumar Moorthy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States. Hauptthemen laut MEDLINE: Cytidine Deaminase, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Cytidine analogues have conferred highly efficacious antimetabolites with broad utility as antiviral and anticancer agents. However, in many cases, human cytidine deaminase (CDA) converts the cytidine-based inhibitor into an inactive uridine metabolite with diminished potency. Inhibitors of CDA are useful agents to boost the efficacy of cytosine- and cytidine-containing drugs by inhibiting their rapid degradation. Toward the goal of developing CDA inhibitors, and our overarching interest in cytosine deaminase enzymes in general, we developed a real-time fluorescence-based deamination activity assay for CDA using isomorphic nucleoside analogues. Base-modified pyrimidine nucleosides that exhibit differential fluorescence properties as either the cytosine or uracil nucleobase were developed. We found that 5-benzo-2-furyl-2'-deoxycytidine is the best fluorescence reporter when implemented in a CDA enzyme activity assay, which permits detailed measurements of the kinetics of CDA activity in the presence or absence of inhibitors. Utilizing this assay, we then screened our in-house collection of 1054 fragments and found 23 hits that were further studied. Two fragment-sized CDA inhibitors with low micromolar potency (200-300 μM) and good ligand efficiency (>0.3) were identified, thereby conferring promising starting points for future inhibitor development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
- Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
- Department of Molecular Biology, University of California - San Diego, La Jolla, California 92093, United States.
ORCID-Profile: Kellan T Passow, Rommie E Amaro, Daniel A Harki
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Moorthy, R., Grillo, M. J., Baur, J. W., Schmidt, S. A., Passow, K. T., Demir, Ö., Tang, J., Olson, M. E., Amaro, R. E., & Harki, D. A. (2025). Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine Deaminase. ACS Chemical Biology, 20(11), 2593-2600. https://doi.org/10.1021/acschembio.5c00394
Vancouver
Moorthy R, Grillo MJ, Baur JW, Schmidt SA, Passow KT, Demir Ö, et al. Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine Deaminase. ACS Chemical Biology. 2025;20(11):2593-2600. doi:10.1021/acschembio.5c00394
BibTeX
@article{Moorthy2025,
author = {Moorthy, Ramkumar and Grillo, Michael J and Baur, Jordan W and Schmidt, Sydney A and Passow, Kellan T and Demir, Özlem and Tang, Jian and Olson, Margaret E and Amaro, Rommie E and Harki, Daniel A},
title = {Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine Deaminase},
journal = {ACS Chemical Biology},
year = {2025},
volume = {20},
number = {11},
pages = {2593--2600},
doi = {10.1021/acschembio.5c00394}
}
EUVIMED